Select drug-substance campaign size and fill cadence when dose strength, formulation holds, line availability, quality release and cold storage change.
Independent model study · RNA manufacturing
Synchronise mRNA drug substance, LNP formulation and sterile filling
Choose campaign and lot sizes that minimise expiry and frozen inventory while respecting formulation, sterile-fill, release and cold-chain constraints.
TemplateIVTPurificationLNP mixingUF/DFSterile filterFill-finish
Decision model
A bounded question with a complete plant consequence.
Template availability through released vial, including nucleotides, lipids, solvents, buffers, consumables, clean utilities, QC holds, cold rooms and disposal.
Equations and accounting rules
dm mRNA/dt = r IVT × V − process lossesDose equivalents = released mRNA mass / dose massLNP material balance closes mRNA, lipids, solvent and bufferFill output = vials/hour × staffed hours × OEEBase, alternative and stress cases
- Three dose strengths
- Monovalent versus multivalent campaign
- LNP yield loss or delayed release
- Shared versus reserved fill-finish capacity
Engineering brief
Model the complete decision, not an isolated unit operation.
BioNTech publicly describes a high-level mRNA sequence spanning IVT, purification and concentration, LNP formulation, sterile filtration, filling and quality control. That is sufficient to frame a product-agnostic scheduling model.
Lipid composition, mixing geometry, impurity clearance, yields and release specifications are not inferred. Dose strength, presentation and stability remain explicit scenario inputs.
01 · Model basis
What the Acatian model needs to resolve
Inputs, mechanisms, limits and outputs remain reviewable on one declared basis.Inputs
IVT volume, productivity and step recoveries
LNP ratio, mixing rate and hold window
Sterile-filter and filling-line capacities
Dose, presentation, release time and cold storage
Mechanisms
dm mRNA/dt = r IVT × V − process losses
Dose equivalents = released mRNA mass / dose mass
LNP material balance closes mRNA, lipids, solvent and buffer
Fill output = vials/hour × staffed hours × OEE
Constraints
Intermediate stability and maximum holds
Formulation and sterile-filter throughput
Fill-line presentation changeovers
QC release and cold-room capacity
Outputs
Released doses, vials and campaign yield
Inventory age, hold compliance and expiry loss
Line, formulation and cold-room utilisation
Material demand, COGS and robustness
02 · Acatian workflow
Build it in six controlled steps
Each step creates a reviewable object, not a hidden spreadsheet assumption.- 01
Declare dose, presentation and campaign basis.
- 02
Close IVT stoichiometry and purification recovery.
- 03
Map LNP formulation and sterile holds.
- 04
Schedule fill-finish, QC and cold storage.
- 05
Stress yields, downtime and release delay.
- 06
Compare released doses, waste and schedule resilience.
03 · Decisions
Questions the model should answer
Which campaign size minimises expiry?
Where should bulk inventory be held?
Is formulation or filling the true constraint?
How does dose strength change annual capacity?
04 · Evidence boundary
Validate before the result carries weight
Validation
Require lot genealogy, component closure, no use before release, no expired intermediate, and reconciliation against authorised batch, filling and QC records.
Limitations
The study does not reproduce a BioNTech formulation or establish clinical, regulatory or GMP suitability. All product-specific inputs require authorised evidence.
Public evidence
What the company context supports—and what it does not.
Sources establish the public process architecture. They do not reveal private operating parameters, site performance or an Acatian relationship.Frequently asked questions
Practical modelling questions
Is this the named organisation's real plant model?
No. It is an independent hypothetical Acatian study based only on the cited public process architecture. It claims no affiliation, endorsement, deployment, confidential data or actual plant performance.
Where do the numerical inputs come from?
Every input must be marked as a public fact, literature estimate, transparent engineering assumption or authorised customer input. The public article does not invent private operating values.
Can the model be calibrated to a real facility?
Yes, when the operator supplies authorised process, equipment, schedule and utility evidence and agrees the intended use, acceptance criteria and validation plan.